Switzerland's inaction on antibiotic development raises global concerns

Antimicrobial resistance (AMR) is no longer a distant theoretical threat; it is a clear and present danger that is already claiming lives at a terrifying rate. In 2019 alone, AMR was responsible for a staggering 1.3 million deaths globally, ranking as the third leading cause of death worldwide. The trajectory is even more harrowing: by 2050, resistance to essential medicines could slaughter up to 10 million people annually—a death toll that rivals the devastation of cancer.

Despite these apocalyptic projections, the global response remains lethargic, and Switzerland—a self-proclaimed pharmaceutical juggernaut—is glaringly absent from the vanguard of solutions. While the world teeters on the edge of a post-antibiotic era where common surgeries could become death sentences, the development of new treatments has ground to a near halt. The crisis is slow-moving, but its momentum is undeniable. Without immediate, aggressive intervention, we face a future where modern medicine's backbone snaps under the weight of evolved bacteria.

The science is difficult, but the economics are disastrous. Developing a single new antibiotic is a Herculean task that consumes 10 to 15 years and burns through over $1 billion (CHF790 million). Yet, the return on this massive investment is negligible. Unlike chronic medication, antibiotics are designed to be cheap and used sparingly—only when absolutely necessary to prevent further resistance. This creates a broken market equation: high risk, astronomical costs, and virtually zero profit.

Consequently, pharmaceutical companies are fleeing the sector in droves. The pipeline for new drugs is drying up just as the pathogens are becoming stronger. To fix this market failure, global health experts are demanding "pull" incentives—subscription models where governments pay an annual fee for access to a drug, guaranteeing revenue regardless of sales volume. It is a proven model being piloted by forward-thinking nations like the UK, Sweden, and Japan. Yet, the industry is paralyzed by a lack of global coordination, waiting for wealthy nations to underwrite the security of global health.

While other nations act, Switzerland dithers. Despite its status as a premier global hub for pharmaceuticals and finance, the Swiss government's progress on implementing life-saving economic incentives is alarmingly sluggish. Current plans indicate that crucial "pull" incentives will not be rolled out until 2029—a four-year delay that the world cannot afford. This procrastination sends a chilling message to the global community.

"If a wealthy country like Switzerland doesn’t join international efforts... this will not send an encouraging signal to other countries and investors," warns Barbara Polek, managing director of the Swiss Round Table on Antibiotics. The risk is not just stalled drugs, but a total brain drain. As Polek notes, researchers are poised to "leave the field entirely" if the sector remains financially unviable. Switzerland has the resources and the reputation to lead; its choice to lag behind is a failure of responsibility that threatens to derail international momentum.

The crisis is already at our doorstep. For doctors like Silvio Brugger at University Hospital Zurich (USZ), the nightmare of untreatable infections is a tangible reality, not a statistic. Brugger recently treated a 44-year-old burn victim infected with Carbapenem-resistant Acinetobacter baumannii (CRAB)—a highly lethal, drug-resistant bacterium.

"The level of resistance was scary," Brugger recounted. The bacteria colonized the patient's nose, lungs, and wounds before invading the bloodstream. Without effective antibiotics, patients like this face a "very high risk of dying." While resistance rates within Switzerland remain relatively low compared to other regions, the global nature of travel means dangerous strains are constantly imported. As the pipeline for new treatments runs dry, Swiss doctors are left fighting 21st-century superbugs with a depleting arsenal, bringing the terrifying prospect of a pre-antibiotic era back to modern Swiss healthcare.